Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

Lärkberget
Download the release

CombiGene AB (publ) (the “Company”) held an extraordinary general meeting (“EGM”) on 10 December 2024 via digital connection. Below is a summary of the decisions passed at the EGM.
 
Amendment of the Articles of Association
The EGM resolved, in accordance with the shareholder Strategic Partner A/S’s proposal, to amend the Articles of Association. The amendment was made in order to expand the scope of the business objectives, whereby the Company shall also have the opportunity to enter into strategic collaborations with other companies in other industries.
 
Board of Directors
The EGM resolved, in accordance with the shareholder Strategic Partner A/S’s proposal, that the Board of Directors shall consist of three ordinary Board members and one deputy Board member. Luca Di Stefano and Jakob Bendtsen were elected, and Marcus Isaksson was re-elected, as ordinary Board members and Lars Thunberg was elected as new deputy Board member. Furthermore, Luca Di Stefano was elected as Chairman of the Board of Directors.

Contacts


CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ), Skeppsbron 38, SE-111 30 Stockholm, Sweden
+46-8-357355 info@combigene.com

About CombiGene


CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is Västra Hamnen Corporate Finance AB.

Sign up here to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.

Attachments


Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.